FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Fulcrum Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$3.70+0.05 (+1.37%)
Close on Oct 19, 2026
- Market cap
- $282.18M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Fulcrum Therapeutics has not reported a dividend
No dividend per share appears in Fulcrum Therapeutics's annual filings since fiscal 2017.